Key result
CyberKnife stereotactic radiosurgery shows clinical and radiographic response without toxicity in recurrent pulmonary artery sarcoma.
Why the study?
Does CyberKnife stereotactic radiosurgery palliate symptoms and provide short-term safety in a patient with recurrent pulmonary artery sarcoma?
Case Report (n=1)
Does CyberKnife stereotactic radiosurgery palliate symptoms and provide short-term safety in a patient with recurrent pulmonary artery sarcoma?
CyberKnife stereotactic radiosurgery may be a feasible and safe short-term palliative option for recurrent pulmonary artery sarcoma.
May support short-term palliation in recurrent pulmonary artery sarcoma; leaves open need for prospective validation.
Pulmonary artery intimal sarcoma is an uncommon tumor with a poor prognosis. We report a case of a 75-year-old man with a pulmonary artery sarcoma, recurrent following surgical resection. To palliate symptoms of this recurrence, he underwent CyberKnife stereotactic radiosurgery with a clinical and radiographic response of his treated disease. No acute or sub-acute toxicity was seen until the patient's death due to metastatic disease 10 weeks following treatment. The feasibility and short-term safety of this technique are reviewed, with emphasis on the stereotactic planning considerations, such as mediastinal organ movement and radiation tolerance.
No takes yet. Share an insight, caveat, or question.
Soltys et al. (2008) conducted a case report in Pulmonary artery intimal sarcoma (n=1). CyberKnife stereotactic radiosurgery was evaluated on Clinical and radiographic response and toxicity. CyberKnife stereotactic radiosurgery provided clinical and radiographic response without acute or sub-acute toxicity in a patient with recurrent pulmonary artery sarcoma.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: